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Abstract Rationale
In utero tobacco exposure is associated with reduced infant lung function. Anti-oxidant enzymes from the glutathione-s-transferase (GST) family may protect against these lung function deficits.
Objectives:
(1) Assess the long-term effect of in utero smoke exposure on lung function into adulthood.
(2) Assess whether GSTT1 and GSTM1 active genotypes have longterm protective effects on lung function.
Methods:
In this longitudinal study, based on a normal population (n=253), lung function was measured during infancy and then at 6, 11, 18 and 24 years. GSTM1 and GSTT1 genotype was analysed in a subgroup (n= 179). Lung function was assessed longitudinally from 6 to 24 years (n=144).
Main Results
Exposure to maternal in utero tobacco was associated with lower FEV1 and FVC from 6 to 24 years (mean difference -3.87% predicted, p=0.021; -3.35% predicted, p=0.035, respectively).
Among those homozygous for the GSTM1 null genotype, in utero tobacco exposure was associated with lower FEV1 and FVC compared with those with no in utero tobacco exposure (mean difference -6.2% predicted, p=0.01; -4.7% predicted, p=0.043 respectively). For those with GSTM1 active genotype, there was no difference in lung function whether exposed to maternal in utero tobacco or not. In utero tobacco exposure was associated with deficits in lung function among those with both GSTT1 null and GSTT1 active genotypes.
Introduction:
The exposure of children's lungs to tobacco smoke is of grave concern as lungs are particularly vulnerable to insult during development. This exposure can occur while still in utero, as nicotine and other toxic substances freely pass through the placenta or postnatally in the home environment 1 .
Exposure to tobacco smoke antenatally is associated with reduced lung function during infancy and childhood 3 4 . Both ante-and post-natal smoke exposure are linked to an increase in respiratory symptoms throughout childhood and adolescence 2 .
We have previously shown that airway function measurements track from infancy into early adulthood indicating an inherent airway structure is laid down early in lung development, while measurements of adult lung size were independent of infant lung function, suggesting lung growth is modifiable by external factors.
Gene-environment interactions modulate the effects of in utero smoke (ITS) exposure on respiratory outcomes in childhood and fetal anti-oxidants may play a role in protecting the developing lungs. Activity levels of glutathione s-transferases (GST), a family of enzymes involved in the detoxification of xenobiotics, vary based on genotype, with homozygous deletions of the GSTT1 and GSTM1 genes associated with absent function of that particular enzyme 5 6 . Among those exposed to ITS, GST active genotypes are linked to higher infant lung function when compared with those with the null genotype, as previously reported in this cohort 7 . GST null genotypes are associated with increased risk of childhood asthma compared with those with active genotypes, particularly in the context of passive smoke exposure, suggesting an increased vulnerability to the detrimental effects of tobacco smoke [8] [9] [10] .
We hypothesised that the negative effect of ITS exposure on lung function would persist into adulthood but that this effect would be lessened for those with higher levels of innate detoxification enzymes. Our aim was to: (1) assess the long-term effects of both ante and postnatal smoke exposure on lung function, as a measure of lung development; and (2) assess whether GSTT1 and GSTM1 active genotypes are protective against the effects of in utero tobacco smoke on lung function through into adulthood.
Methods and Materials:
The Perth Infant Asthma Follow study was established in 1987. Over 24 months, 253 subjects were recruited antenatally from an urban maternity hospital in Perth, Western Australia. There was no preselection based on family history of asthma or atopy. Recruitment details have been published previously 11 . Infants were excluded if they were born premature <37 weeks gestation, had any major congenital abnormality or had any significant respiratory illnesses in the first month of life.
Detailed antenatal smoking history during each trimester of the pregnancy was collected from both parents. Fetal in utero tobacco exposure was classified as positive for maternal or paternal exposure if that parent smoked at all during the pregnancy. Subjects could be positive for both maternal and paternal in utero tobacco exposure. Subjects were classified as negative for any ITS exposure if neither parent smoked at all during the pregnancy.
Urinary cotinine, a byproduct of nicotine metabolism, was measured in a subgroup of infants at birth (n=85).
Subjects or their parents also completed a questionnaire at each follow-up assessment 12 . This included questions on history of physician-diagnosed asthma and tobacco smoke exposure in the household. "Postnatal smoke exposure only" was classified as a positive response to post-natal smoke exposure at either 1, 6 or 11 years of age and no history of maternal in utero smoke exposure. "Incomplete postnatal data" was recorded if there was less than 2 postnatal assessments.
The participants performed lung function testing at regular intervals from infancy through to young adulthood at 1 month, 6 months, 12 months, 6, 11, 18 and 24 years of age.
The rapid thoraco-abdominal compression technique during tidal breathing of sedated infants was used during infant lung function testing 13 . The interaction between in utero tobacco exposure and GST genotype on infant lung function in this cohort has been published previously 7 .
Spirometry was performed at each assessment from 6 to 24 years 14 . FEV1, FVC, FEF25-75%
and FEV1/FVC were recorded and converted into percent predicted scores based on sex, age, height and ethnicity using GLI reference values 15 .
GST genotyping analysis was performed on blood samples taken at either the 6 or 11 year assessments. GSTT1 and GSTM1 deletion polymorphisms were identified by polymerase chain reaction (PCR) methods as previously described in detail 7 16 . A subset of specimens had genotype results confirmed by PCR with a second set of primers 7 . CYP1A1 primers were used as a positive control for each PCR performed. Those who were homozygous for the GST null genes were classified as GST null and those who were either heterozygous or homozygous for non-null GST genotype was classified as GST active. 
Statistical analysis:
Comparisons between the participants seen at each assessment was analysed by Pearson's chisquare for categorical variables and independent t-test for continuous variables.
Mean difference in cotinine levels between infants whose mothers reported smoking at recruitment and infants whose mothers reported not smoking at recruitment were measured using the Mann Whitney U test.
In the longitudinal analysis, the link between tobacco smoke exposure or GST genotype and lung function from 6 to 24 years were assessed by generalised estimating equations. These equations adjust for inherent covariance in each subject 17. Mean lung function results (FEV1, FVC, FEF25-75% and FEV1/FVC% predicted) from the 6, 11, 18 and 24 year assessments were the longitudinal outcome variables for each participant.
Maternal ITS, paternal ITS and postnatal tobacco exposure only were all assessed separately and compared with no in utero smoke exposure.
In order to assess the effect of GST polymorphisms on lung function in the context of in utero tobacco exposure, we then split the group into GST genotype i.e firstly GSTT1 null versus GSTT1 active and then GSTM1 null and GSTM1 active and applied the generalised estimating equations. Mean longitudinal lung function (% predicted) for those exposed and not exposed to maternal ITS in each subgroup were included as outcome variables.
Two-sided p value <0.05 determined statistical significance.
This study had a power of 0.813 to reject the null hypothesis of no significant difference in FEV1 between GSTT1 null and GSTT1 non-null genotype groups based on 411 assessments, if the real difference between groups was 5% predicted, with standard deviation of 12%
predicted. The Type I error probability associated with this test of this null hypothesis is 0.05. Lung function testing was performed on 110 subjects at 6 years, 183 at 11 years, 141 at 18 years and 118 subjects at 24 years. Comparison of subject characteristics at each assessment have previously been published 18 . The only significant difference between the original cohort and those seen at follow up was less parental ITS exposure in those seen at later follow ups (54% ITS exposure in original cohort; 45% of those seen at 18 years; 43% of those seen at 24 years). GSTT1 and GSTM1 genotyping was performed on 179 subjects and the frequency of each genotype is presented in table 1. There were 144 subjects with 443 assessments included in the longitudinal analysis of smoke exposure, and 128 subjects with 411 assessments in the longitudinal analysis of GST genotype and smoke exposure.
Cotinine levels and maternal smoke exposure Neonatal cotinine levels were higher amongst infants whose mothers reported smoking at recruitment during pregnancy (n=25; mean 75.3ng/ml creatinine, SD 57.7), than those whose mothers reported no smoking at recruitment (n=60; mean 9.3ng/ml creatinine, SD 30.5), p<0.001.
In utero tobacco smoke exposure and lung function Exposure to maternal ITS was associated with significantly lower FEV1 and FVC from 6 to 24 years of age (mean difference -3.87% predicted, p=0.021, and -3.35% predicted, p=0.035, respectively) Figure 1 ; supplementary figure 2 ). However, only three subjects with exposure to maternal ITS had the GSTT1 null genotype and all three also had the GSTM1 null genotype.
Discussion:
This longitudinal, birth-cohort study of lung function confirms that maternal ITS exposure is A further important finding was evidence suggesting that the presence of active glutathione stransferase enzymes provide longterm protection from the damage caused by maternal ITS exposure. In particular, the functional GSTM1 active genotype appears to have this protective effect. Maternal ITS was only associated with deficits in lung function up to adulthood for those with the GSTM1 null genotype and not for those with the GSTM1 active genotype. The functional GSTT1 active genotype did not appear to share this degree of protective effect, as those with this genotype still had significant deficits in lung function if exposed to maternal ITS compared with those with no ITS exposure. However, the difference between those exposed and not exposed was smaller than among the GSTT1 null genotype group suggesting that GSTT1 active may still provide a degree of protection, although not enough to fully overcome the damage associated with ITS exposure. GSTT1 may be of more importance in protection very early on, as in a previous study from this cohort, GSTT1 active genotype was associated with higher lung function during infancy mong those exposed to maternal ITS than the GSTT1 null group 7 .
Glutathione s-transferase is an enzyme which catalyses the reaction between glutathione and electrophilic xenobiotics and reactive oxygen species, making it crucial to the body's detoxification processes 19 . There are eight classes of cytosolic GST in humans, each with several subclasses, which vary in their structure and substrate specificity 20 . Although nicotine is not metabolised by the GST enzymes, many of the other toxic substances within cigarettes are 21 22 . Homozygous GSTM1 and GSTT1 null polymorphisms have been associated with the development of asthma in childhood, thought to be due to an increase in oxidative stress, although they are not related to asthma severity (turner new paper). Adjusting for confounding variables during childhood such as tobacco exposure and environmental pollution is difficult and may be the reason results from previous studies have not been convincing 23 . GSTM1 and GSTT1 null genotypes have both been found to be strong predictors of COPD in adult females 24 . The GSTM1 null genotype is also associated with reduced lung function growth in children, while the GSTT1 null genotype is associated with accelerated lung function decline in adult males 25 26 . However, these studies did not specifically investigate those exposed to tobacco smoke in utero, a critical time during lung development and we did not find a link between GST genotype and lung function among those not exposed to ITS.
The GSTT1 null genotype is rarer than the GSTM1 null genotype, affecting only 15% of the population. The subject numbers with both GSM1 null genotype and maternal ITS exposure, n=3, make definitive statements about this group difficult. However, the length of follow up from infancy through into early adulthood in this study is an important advantage, as this spans the entire post-natal lung growth phase, to the peak in lung function in early adulthood.
During the in utero period of organogenesis, the fetus is exposed to the same levels of nicotine and other toxic substances as found in the actively-smoking mother, as these toxic substances pass freely through the placenta. Cotinine, a by-product of nicotine metabolism, can be measured in umbilical cord blood of newborn infants whose mothers smoked during pregnancy 1 . Although the tobacco is not inhaled into the lungs of the fetus, the serum exposure to these toxins is associated with reduced lung function when measured in the first few days of life, even before any post-natal tobacco smoke expsoure 27 . Given the negative associations between tobacco exposure while pregnant and infant outcomes, pregnant mothers may be reluctant to admit smoking to study researchers. However we collected objective evidence of tobacco exposure, with neonatal urinary cotinine levels, which confirm the reliability of the parent reported smoking data.
Interestingly, there was no link between either paternal ITS exposure or postnatal tobacco smoke exposure alone, on lung function throughout childhood, suggesting the most significant impact of tobacco exposure on lung function is a dose response effect during the in utero developmental phase.
Children with two hits, a toxic exposure and a genetic vulnerability, are at risk for the largest deficits in lung growth during lung development. Our data suggests there is a protective benefit in having higher anti-oxidant levels during in utero development and this warrants further Table 2 . Association between maternal in utero tobacco smoke exposure and lung function from 6-24 years, grouped by GST genotype. 
